(MedPage Today) — When U.S. health officials meet next month to reconsider a list of controversial peptide drugs, they will hear from a new set of voices: doctors and pharmacists with deep financial ties to the burgeoning industry of unproven…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/121978
Author :
Publish date : 2026-06-29 21:23:00
Copyright for syndicated content belongs to the linked Source.
